Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2010-021444-18-GB
EUCTR2010-021444-18-GBActive, not recruitingPhase 1

TO ESTABLISH THE FEASIBILITY OF COMBINING EITHER THE TYROSINE KINASE INHIBITOR AC220 OR THE CXCR4 INHIBITOR PLERIXAFOR OR THE HSP90 INHIBITOR, GANETESPIB, WITH CHEMOTHERAPY IN OLDER PATIENTS WITH ACUTE MYELOID LEUKAEMIA AND HIGH RISK MYELODYSPLASTIC SYNDROME - AML 18 Pilot Trial

Cardiff University0 sites90 target enrollmentStarted: October 8, 2010Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Drugs

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Enrollment
90
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Inclusion Criteria

  • •1) They have one of the forms of AML, except Acute Promyelocytic Leukaemia as defined by the WHO Classifcation - this can be any type of de novo or secondary AML - or high risk MDS, defined as greater than 10% marrow blasts.
  • •2) Serum creatinine = 1.5xULN.
  • •3) White cell count of <30x10^9/L at diagnosis (for Plerixafor option only).
  • •4) Serum potassium, magnesium and calcium levels should be at least within institutional normal limits.
  • •5) Total serum bilirubin = 1.5xULN and serum aspartate transaminase and/or alanine transaminase = 2.5xULN
  • •6) Sexually mature males must agree to use an adequate and medically accepted method of contraception throughout the study if their sexual partners are women of child bearing potential (WOCBP)
  • •7) Over 60 years of age
  • •8) Provided written informed consent
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range: 0
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 0
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 80

Exclusion Criteria

  • •1)They have previously received cytotoxic chemotherapy for AML (hydroxycarbimide, or similar low-dose therapy, to control the white count prior to initiation of intensive therapy is not an exclusion)
  • •2) They are in blast transformation of chronic myeloid leukaemia (CML)
  • •3) They have a concurrent active malignancy excluding basal cell carcinoma
  • •4) They are pregnant or lactating
  • •5) They have Acute Promyelocytic Leukaemia
  • •6) Known infection with human immunodeficiency virus (HIV)
  • •7) Patients are not eligible for the AC220 option if they have:
  • •-Uncontrolled or significant cardiovascular disease including:
  • •-A myocardial infarction within 12 months
  • •-Uncontrolled angina within 6 months
  • •-Current, or history of, congestive heart failure New York Heart Association (NYHA) class 3 or 4, unless an echocardiogram or Multiple Gated Acquisition Scan performed either within 1 month prior to study screening or during screening results in a left ventricular ejection fraction that is =45% (or institutional lower limit of normal value)
  • •-Diagnosed or suspected congenital long QT syndrome. Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes); any history of arrhythmia will be discussed with the Sponsor's Medical Monitor prior to patient's entry into the study.
  • •-Prolonged QTcF interval on pre-entry ECG (=450ms)
  • •-Any history of second or third degree heart block (may be eligible if the patient currently has a pacemaker)
  • •-Heart rate <50/min on pre-entry ECG
  • •-Uncontrolled hypertension
  • •-Obligate need for a cardiac pacemaker
  • •-Complete left bundle branch block
  • •-Atrial fibrillation

Investigators

Similar Trials

Completed
Not Applicable
Assessing the feasibility of osteopathy and psycho-education based therapy application in managing stress
ACTRN12620000763943The Unitec Institute of Technology18
Completed
Not Applicable
An integrated malaria control strategy including community case management and Seasonal Malaria Chemoprevention in Senegal.Malaria
PACTR201305000551876niversity Cheikh Anta DIOP of Dakar1,000
Completed
Not Applicable
A phase Ib feasibility study of the combination of panobinostat and midostaurin in recipients of allogeneic stem cell transplantation with FLT3-ITD AMAcute myeloid leukemiaAML
NL-OMON48580HOVO15
Active, not recruiting
Not Applicable
A study to evaluate the efficacy and safety of combination chemotherapy of panobinostat and decitabine, given after donor stem cell transplantation in patients with (very) poor risk AM(very) poor risk AML or RAEB with IPSS = 1.5MedDRA version: 18.0Level: LLTClassification code 10024329Term: LeukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: PTClassification code 10028533Term: Myelodysplastic syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2012-003344-74-BEHOVON Foundation100
Active, not recruiting
Phase 1
A study about the treatment of patients with a specific type of AML with a combination of panobinostat and midostaurin during 1 year after allogeneic stem cell transplantation .
EUCTR2017-002335-42-NLHOVON Foundation40